K

Kyverna Therapeutics
D

KYTX

8.77000
USD
0.43
(5.16%)
مغلق
حجم التداول
41,920
الربح لكل سهم
-4
العائد الربحي
-
P/E
-2
حجم السوق
384,092,411
المقالات

العنوان: Kyverna Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.